Press release
May 18, 2026
Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas
Parabilis Medicines, Inc. (PBLS)
The multi-target collaboration combines Parabilis’s novel Helicon™ peptide platform with Regeneron’s industry-leading antibody capabilities Agreement provides for Parabilis to receive $125M from Regeneron, including a $50M upfront payment and a $75M equity commitment, with up to approximately $2.2B